Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Details

• Lead Sponsor: David Lacomis, MD; University of Pittsburgh
• Collaborator: Jacobus Pharmaceutical
• Treatments: 3,4-diaminopyridine; 4-Aminopyridine; Amifampridine

Criteria

Inclusion Criteria:

1. Diagnosis of LEMS

2. Over 18 years old

3. Medically stable

4. If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study

Exclusion Criteria:

1. Known sensitivity to 3,4 DAP

2. History of past or current seizures

3. History of severe asthma

4. Believed by the investigator to be unable to comply with the protocol

5. Unable to provide informed consent